NovoCure Limited
NVCR
$16.69
-$0.11-0.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.46% | -40.02% | 38.22% | 41.87% | 26.95% |
| Total Depreciation and Amortization | 18.12% | 19.74% | -12.31% | 5.03% | 3.42% |
| Total Amortization of Deferred Charges | -- | 12.06% | -- | -- | -- |
| Total Other Non-Cash Items | -26.64% | 1,076.74% | 7.93% | -14.94% | -8.18% |
| Change in Net Operating Assets | -2.80% | -79.20% | 164.32% | 62.75% | -8,971.53% |
| Cash from Operations | -12.96% | 76.29% | 153.72% | 92.44% | -88.76% |
| Capital Expenditure | 9.95% | -31.10% | -47.29% | -65.14% | -93.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -98.40% | -112.60% | -14.83% | -5,110.94% | 191.94% |
| Cash from Investing | -102.63% | -122.55% | -40.94% | -2,594.39% | 199.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -430,333.33% | -- |
| Issuance of Common Stock | 2,363.38% | 40.58% | -91.46% | -55.92% | -95.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,363.38% | 40.58% | -91.46% | 1,063.92% | -95.91% |
| Foreign Exchange rate Adjustments | 505.36% | -164.00% | 189.69% | -492.31% | -236.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.07% | -126.85% | 2,213.65% | -891.32% | 203.37% |